Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis

References

• Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323:1945–1960
   PubMed Web of Science ®Google Scholar
• Kumar B, Saraswat A, Kaur I. Palmoplantar lesions in psoriasis: a study of 3065 patients. Acta Derm Venereol. 2002;82(3):192–195. Internet Available from. doi: 10.1080/00015550260132488.
   PubMed Web of Science ®Google Scholar
• Farley E, Masrour S, McKey J, et al. Palmoplantar psoriasis: a phenotypical and clinical review with introduction of a new quality-of-life assessment tool. J Am Acad Dermatol. 2009;60(6):1024–1031. doi: 10.1016/j.jaad.2008.11.910
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Massone C. Can we really separate palmoplantar pustulosis from psoriasis? J Eur Acad Dermatol Venereol England. 2010;24(5):619–621. author reply 621. doi: 10.1111/j.1468-3083.2010.03648.x
   PubMed Web of Science ®Google Scholar
• Brunasso AMG, Puntoni M, Aberer W, et al. Clinical and epidemiological comparison of patients affected by palmoplantar plaque psoriasis and palmoplantar pustulosis: a case series study. Br J Dermatol. 2013;168(6):1243–1251. doi: 10.1111/bjd.12223
   PubMed Web of Science ®Google Scholar
• Barber HW. Acrodermatitis continua vel perstans (dermatitis repens) and psoriasis pustulosa*. Br J Dermatol. 1930;42:500–518. Internet Available from doi: 10.1111/j.1365-2133.1930.tb09380.x
   Google Scholar
• Andrews GC, Birkman FW, Kelly RJ. Recalcitrant pustular eruptions of the palms and soles. Arch Dermatol. 1934;29(4):548–563. Internet Available from. doi: 10.1001/archderm.1934.01460100066006
   Google Scholar
• Uppala R, Tsoi LC, Harms PW, et al. “Autoinflammatory psoriasis”—genetics and biology of pustular psoriasis. Cell Mol Immunol. 2021;18(2):307–317. doi: 10.1038/s41423-020-0519-3
   PubMed Web of Science ®Google Scholar
• Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11:1917–1929. doi: 10.1007/s13555-021-00612-x Internet Available from.
   PubMed Web of Science ®Google Scholar
• Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar Pustulosis: recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2020;21:355–370. doi: 10.1007/s40257-020-00503-5 Internet Available from.
   PubMed Web of Science ®Google Scholar
• Raposo I, Torres T. Palmoplantar psoriasis and palmoplantar Pustulosis: Current treatment and future prospects. Am J Clin Dermatol. 2016;17(4):349–358. doi: 10.1007/s40257-016-0191-7
   PubMed Web of Science ®Google Scholar
• Chung J, Callis Duffin K, Takeshita J, et al. Palmoplantar psoriasis is associated with greater impairment of health-related quality of life compared with moderate to severe plaque psoriasis. J Am Acad Dermatol. 2014;71(4):623–632. Internet Available from. doi: 10.1016/j.jaad.2014.04.063
   PubMed Web of Science ®Google Scholar
• Engin B, Ö A, Tüzün Y. Palmoplantar psoriasis. Clinics In Dermatology. 2017;35(1):19–27. doi: 10.1016/j.clindermatol.2016.09.004
   PubMed Web of Science ®Google Scholar
• Spencer RK, Elhage KG, Jin JQ, et al. Apremilast in palmoplantar psoriasis and palmoplantar Pustulosis: a systematic review and meta-analysis. Dermatol Ther (Heidelb). 2023;13(2):437–451. doi: 10.1007/s13555-022-00877-w
   PubMed Web of Science ®Google Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: focus on elderly patients. Expert Opin Drug Saf. 2023;22:43–58. Internet Available from. doi: 10.1080/14740338.2023.2173171
   PubMed Web of Science ®Google Scholar
• Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J DermatolTreat. 2022;33:2813–2820. Internet Available from. doi: 10.1080/09546634.2022.2081655.
   Google Scholar
• Sbidian E, Chaimani A, Guelimi R, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta‐analysis. Cochrane Database Of Systematic Reviews. 2023;2023(7): [Internet]. 2023; Available from. doi: 10.1002/14651858.CD011535.pub6.
   PubMedGoogle Scholar
• Megna M, Camela E, Battista T, et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients. Expert Opin Drug Saf. 2023;22:25–41. Internet Available from. doi: 10.1080/14740338.2023.2173170
   PubMed Web of Science ®Google Scholar
• Kim WB, Jerome D, Yeung J. Diagnosis and management of psoriasis. Can Fam Physician. 2017;63:278–285.
   PubMed Web of Science ®Google Scholar
• Megna M, Marano L, Camela E, et al. A case of severe psoriatic arthritis with hands flexion contracture and palmar psoriasis successfully treated with guselkumab. Dermatol Ther. 2022;35:e15766. Internet Available from. doi: 10.1111/dth.15766.
   PubMed Web of Science ®Google Scholar
• Egeberg A, See K, Garrelts A, et al. Epidemiology of psoriasis in hard-to-treat body locations: data from the Danish skin cohort. BMC Dermatol. 2020;20(1):1–8. doi: 10.1186/s12895-020-00099-7
   PubMed Web of Science ®Google Scholar
• Husein-ElAhmed H, Husein-ElAhmed S. Bayesian network meta-analysis of head-to-head trials for complete resolution of nail psoriasis. Clinical And Experimental Dermatology. 2023;48(8):895–902. doi: 10.1093/ced/llad136
   PubMed Web of Science ®Google Scholar
• Reich K, Conrad C, Kristensen LE, et al. Network meta-analysis comparing the efficacy of biologic treatments for achieving complete resolution of nail psoriasis. J DermatolTreat. 2022;33(3):1652–1660. doi: 10.1080/09546634.2021.1892024
   Google Scholar
• Huang I-H, Wu P-C, Yang T-H, et al. Small molecule inhibitors and biologics in treating nail psoriasis: a systematic review and network meta-analysis. J Am Acad Dermatol. 2021;85(1):135–143. doi: 10.1016/j.jaad.2021.01.024
   PubMed Web of Science ®Google Scholar
• Szebényi J, Gede N, Hegyi P, et al. Efficacy of biologics Targeting Tumour Necrosis Factor-alpha, interleukin-17 -12/23, -23 and small molecules Targeting JAK and PDE4 in the treatment of nail psoriasis: A network meta-analysis. Acta Derm Venereol. 2020;100:adv00318. doi: 10.2340/00015555-3640
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. Internet Available from: http://www.bmj.com/content/372/bmj.n71.abstract
   PubMed Web of Science ®Google Scholar
• Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi: 10.1186/s13643-016-0384-4
   PubMedGoogle Scholar
• Sterne JAC, Savović J, Page M, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. Br Med J. 2019;366:l4898. doi: 10.1136/bmj.l4898
   PubMed Web of Science ®Google Scholar
• Salanti G. Indirect and mixed-treatment comparison, network, or multiple-treatments meta-analysis: many names, many benefits, many concerns for the next generation evidence synthesis tool. Res Synth Methods. 2012;3(2):80–97. doi: 10.1002/jrsm.1037
   PubMed Web of Science ®Google Scholar
• Rücker G, Schwarzer G. Reduce dimension or reduce weights? Comparing two approaches to multi-arm studies in network meta-analysis. Stat Med. 2014;33(25):4353–4369. doi: 10.1002/sim.6236
   PubMed Web of Science ®Google Scholar
• R Core Team (2021). R: a language and environment for statistical computing [Internet]. R Foundation for Statistical Computing, Vienna Austria; Available from: https://www.r-project.org/.
   Google Scholar
• Balduzzi S, Rücker G, Nikolakopoulou A, et al. Netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106(2). doi: 10.18637/jss.v106.i02
   Web of Science ®Google Scholar
• Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. doi: 10.1186/s12874-015-0060-8 Internet Available from.
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Jackson D, Barrett JK, et al. Consistency and inconsistency in network meta‐analysis: concepts and models for multi‐arm studies. Res Synth Methods. 2012;3(2):98–110. doi: 10.1002/jrsm.1044
   PubMed Web of Science ®Google Scholar
• Dias S, Welton NJ, Caldwell DM, et al. Checking consistency in mixed treatment comparison meta-analysis. Stat Med. 2010;29:932–944. Internet Available from. doi: 10.1002/sim.3767.
   PubMed Web of Science ®Google Scholar
• Warren RB, Morita A, Menter A, et al. Efficacy and safety of ixekizumab compared to etanercept or placebo treatment of patients with moderate-to-severe plaque psoriasis and palmoplantar involvement over a 60-week dosing period: results from UNCOVER-3, a phase 3 trial. J Eur Acad Dermatol Venereol. 2016;30:78‐79. Internet Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01771542/full
   Web of Science ®Google Scholar
• Papp K, Lebwohl M, Gottlieb AB, et al. Bimekizumab for the treatment of moderate to-severe plaque psoriasis with scalp, nail and palmoplantar involvement through 52 weeks: post-hoc analysis from the BE VIVID phase III trial. J Of Skin. 2021;5(1):S22‐. Internet Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-02285967/full
   Google Scholar
• Blauvelt A, Papp K, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017 Mar;76(3):405–417. doi:10.1016/j.jaad.2016.
   PubMed Web of Science ®Google Scholar
• EUCTR2012-005412-25-BE. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2012-005412-25-BE.
   Google Scholar
• EUCTR2013-003086-34-BE. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe chronic palmoplantar pustular psoriasis. [Internet]. 2013; Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01854113/full.
   Google Scholar
• Gottlieb A, Sullivan J, Van Doorn M, et al. Secukinumab is effective in subjects with moderate to severe palmoplantar psoriasis: 16 week results from the GESTURE study. Australas J Dermatology Conf 49th Annu Sci Meet Australas Coll Dermatologists Perth, WA Aust Conf Start 20160514 Conf End 20160517 Conf Publ [Internet]. 2016;57:76‐77. Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01266734/full
   Google Scholar
• Gottlieb A, Sullivan J, van Doorn M, et al. Secukinumab shows significant efficacy in palmoplantar psoriasis: results from GESTURE, a randomized controlled trial. J Am Acad Dermatol. 2017;76(1):70–80. doi: 10.1016/j.jaad.2016.07.058
   PubMed Web of Science ®Google Scholar
• Leonardi C, Langley RG, Papp K, et al. Adalimumab for treatment of moderate to severe chronic plaque psoriasis of the hands and feet: efficacy and safety results from REACH, a randomized, placebo-controlled, double-blind trial. Arch Dermatol. 2011;147(4):429–436. doi: 10.1001/archdermatol.2010.384
   PubMed Web of Science ®Google Scholar
• Menter A, Bagel J, Unnebrink K, et al. Clinical and patient-reported improvements of hand and/or foot psoriasis with adalimumab: subanalysis of REACH. J Am Acad Dermatol. 2012;66. Internet AB187 Available from https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01034408/full
   Web of Science ®Google Scholar
• Menter A, Reich K, Warren RB, et al. 056 impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2. J Invest Dermatol. 2016;136(9):S170. Internet Available from. doi: 10.1016/j.jid.2016.06.073
   Web of Science ®Google Scholar
• Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80(5):1344–1352. doi: 10.1016/j.jaad.2019.01.066
   PubMed Web of Science ®Google Scholar
• NCT00585650. Study of Tumor Necrosis Factor Receptor Fusion Protein etanercept (Enbrel) in psoriasis of the hands and/or feet. https://clinicaltrials.gov/show/NCT00585650.
   Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy of guselkumab in patients with moderate-to-severe plaque psoriasis with involvement of the scalp, nails, hands, and feet: results from the phase 3 VOYAGE 2 study. J Am Acad Dermatol. 2017;76:AB120‐. Internet Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01735483/full
   Web of Science ®Google Scholar
• NCT00629772. Safety and efficacy of infliximab in palmoplantar psoriasis. https://clinicaltrials.gov/ct2/show/NCT00629772.
   Google Scholar
• NCT00735787. Controlled study of Humira in subjects with chronic plaque psoriasis of the hands and/or feet. [Internet]. 2008; Available from: https://doi.org/10.1002/central/CN-02016887/full.
   Google Scholar
• NCT01474512. A phase 3 study in participants with moderate to severe psoriasis (p. UNCOVER–1).
   Google Scholar
• NCT01597245. A phase 3 study in participants with moderate to severe psoriasis (UNCOVER-2) (p. UNCOVER–2).
   Google Scholar
• NCT01646177. A study in participants with moderate to severe psoriasis (UNCOVER-3) (p. UNCOVER–3).
   Google Scholar
• NCT01806597. Study of safety, tolerability, and efficacy of secukinumab in subjects with moderate to severe palmoplantar psoriasis. https://clinicaltrials.gov/ct2/show/NCT01806597.
   Google Scholar
• NCT02008890. Palmoplantar pustular psoriasis efficacy and safety with secukinumab. https://clinicaltrials.gov/ct2/show/NCT02008890.
   Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial. Journal Of The American Academy Of Dermatology. 2017;76(3):418–431. Internet Available from. doi: 10.1016/j.jaad.2016.11.042
   PubMed Web of Science ®Google Scholar
• Bimzelx: EPAR - Product information. https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx. 2022;
   Google Scholar
• Taltz: EPAR - Product information. https://www.ema.europa.eu/en/medicines/human/EPAR/taltz. 2022;
   Google Scholar
• Tremfya: EPAR - Product information. https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya. 2022;
   Google Scholar
• Bissonnette R, Poulin Y, Guenther L, et al. Treatment of palmoplantar psoriasis with infliximab: a randomized, double-blind placebo-controlled study. J Eur Acad Dermatol Venereol. 2011;25(12):1402–1408. doi: 10.1111/j.1468-3083.2011.03984.x
   PubMed Web of Science ®Google Scholar
• Blauvelt A, KA P, CE G, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator- [Internet]. J. Am. Acad. Dermatol. United States; 2017. p. 405–417. Available from: https://pubmed.ncbi.nlm.nih.gov/28057360/.
   Google Scholar
• Blauvelt A, Papp K, Griffiths CEM, et al. Efficacy of guselkumab within specific body regions in patients with moderate-to-severe plaque psoriasis: results from the phase 3-VOYAGE 1 study. Australas J Dermatol. 2017;58:40‐. Internet Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01378811/full
   Web of Science ®Google Scholar
• NCT02641730. An efficacy and safety of guselkumab in participants with Palmoplantar Pustulosis. https://clinicaltrials.gov/ct2/show/NCT02641730.
   Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153–1161. doi: 10.1001/jamadermatol.2019.1394
   PubMed Web of Science ®Google Scholar
• Bissonnette R, Lynde CW, Krueger JG, et al. Interleukins-23 and-17 in patients with palmoplantar pustular psoriasis and palmoplantar pustulosis. J Am Acad Dermatol. 2013;68:AB201. Internet Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01028478/full
   Web of Science ®Google Scholar
• Bissonnette R, Nigen S, Langley RG, et al. Increased expression of IL-17A and limited involvement of IL-23 in patients with palmo-plantar (PP) pustular psoriasis or PP pustulosis; results from a randomised controlled trial. J Eur Acad Dermatol Venereol. 2014;28(10):1298–1305. doi: 10.1111/jdv.12272
   PubMed Web of Science ®Google Scholar
• Higgins JPT, Thomas J, Chandler J, et al. Page MJ WV (editors). Cochrane Handbook For Systematic Reviews Of Interventions Version 6.3 (updatedFeb 2022). 2022 Available from www.training.cochrane.org/handbook.
   Google Scholar
• Spencer RK, Jin JQ, Elhage KG, et al. Comparative efficacy of biologics and oral agents in palmoplantar psoriasis and palmoplantar pustulosis: a systematic review and network meta-analysis of randomized clinical trials. J Am Acad Dermatol. 2023;89(2):423–425. Internet Available from. doi: 10.1016/j.jaad.2023.04.043
   PubMed Web of Science ®Google Scholar
• Paller AS, Seyger MMB, Alejandro Magariños G, et al. Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS). Br J Dermatol. 2020;183(2):231–241. doi: 10.1111/bjd.19147
   PubMed Web of Science ®Google Scholar
• Paul C, Reich K, Gottlieb AB, et al. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014;28(12):1670–1675. doi: 10.1111/jdv.12359
   PubMed Web of Science ®Google Scholar
• Sigurgeirsson B, Kircik L, Nemoto O, et al. Secukinumab improves the signs and symptoms of moderate-to-severe plaque psoriasis in subjects with involvement of hands and/or feet: subanalysis of a randomized, double-blind, placebo-controlled, phase 2 dose-ranging study. J Eur Acad Dermatol Venereol England. 2014;28(8):1127–1129. doi: 10.1111/jdv.12343
   PubMed Web of Science ®Google Scholar
• Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab, an anti–interleukin 23 monoclonal antibody, for Palmoplantar Pustulosis. JAMA Dermatol. 2018;154(3):309–316. doi: 10.1001/jamadermatol.2017.5937
   PubMed Web of Science ®Google Scholar
• Skyrizi: EPAR - Product information. https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi. 2022;
   Google Scholar
• EUCTR2016-003718-28-DE. Study comparing risankizumab and Fumaderm, for the treatment of a moderate to severe inflammatory disease of the skin called psoriasis in patients who have never been treated with oral or injectable drugs. Patients Will Know Which Drug They Receive, Thep.[Internet]. 2017; Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01905825/full.
   Google Scholar
• EUCTR2015-000892-28-NL. A phase 3b trial of ixekizumab compared to ustekinumab (Stelara) in moderate to severe psoriasis. [Internet]. 2015; Available from: https://www.cochranelibrary.com/central/doi/10.1002/central/CN-01829445/full.
   Google Scholar
• Orsini D, Gargiulo L, Ibba L, et al. Effectiveness of risankizumab in plaque psoriasis with involvement of difficult-to-treat areas: a real-world experience from two referral centers. J DermatolTreat. 2023;34:2220849. Internet Available from. doi: 10.1080/09546634.2023.2220849
   Google Scholar
• Cannizzaro MV, Coscarella G, Chiricozzi A. Brodalumab in the treatment of plaque psoriasis localized in difficult-to-treat areas: a narrative review. Dermatol Pract Concept. 2023;13:e2023245. doi: 10.5826/dpc.1303a245
   PubMedGoogle Scholar
• Ibba L, Gargiulo L, Alfano A, et al. Anti-IL-23 and anti-IL-17 drugs for the treatment of non-pustular palmoplantar psoriasis: a real-life retrospective study. J DermatolTreat. 2023;34:2199108. Internet Available from. doi: 10.1080/09546634.2023.2199108
   Google Scholar
• Mastorino L, Burzi L, Frigatti G, et al. Clinical effectiveness of IL-17 and IL-23 inhibitors on difficult-to-treat psoriasis areas (scalp, genital, and palmoplantar sites): a retrospective, observational, single-center, real-life study. Expert Opin Biol Ther. 2023;23(9):929–936. doi: 10.1080/14712598.2023.2236023
   PubMed Web of Science ®Google Scholar
• Piaserico S, Riedl E, Pavlovsky L, et al. Comparative effectiveness of biologics for patients with moderate-to-severe psoriasis and special area involvement: week 12 results from the observational psoriasis study of health outcomes (PSoHO). Front Med. 2023;10:10. doi: 10.3389/fmed.2023.1185523
   Web of Science ®Google Scholar
• Riggioni C, Alvaro-Lozano M, Alsina L. Biologics as a therapeutic approach for a Th17-mediated severe dermatitis in skin barrier disorders. Allergy. 2020;75(11):3007–3008. doi: 10.1111/all.14475
   PubMed Web of Science ®Google Scholar
• Simopoulou T, Sotirios GTE, Bogdanos DP. Secukinumab, ixekizumab, bimekizumab and brodalumab for the treatment of psoriasis and psoriatic arthritis. Immunotherapy. 2015;7(4):323–333. doi: 10.2217/imt.14.113
   PubMedGoogle Scholar
• Funk PJ, Perche PO, Singh R, et al. Comparing available JAK inhibitors for treating patients with psoriasis. Expert Rev Clin Immunol. 2022;18(3):281–294. Internet Available from. doi: 10.1080/1744666X.2022.2039121
   PubMed Web of Science ®Google Scholar
• Lé AM, Puig L, Torres T. Deucravacitinib for the treatment of psoriatic disease. Am J Clin Dermatol. 2022;23(6):813–822. doi: 10.1007/s40257-022-00720-0
   PubMed Web of Science ®Google Scholar
• Camela E, Potestio L, Fabbrocini G, et al. The holistic approach to psoriasis patients with comorbidities: the role of investigational drugs. Expert Opin Investig Drugs. 2023;32:537–552. Internet Available from. doi: 10.1080/13543784.2023.2219387
   PubMed Web of Science ®Google Scholar